PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-272.88%
Negative net income growth while AVXL stands at 0.96%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
77.92%
D&A growth of 77.92% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
100.00%
Deferred tax of 100.00% while AVXL is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
49.65%
SBC growth while AVXL is negative at -98.43%. John Neff would see competitor possibly controlling share issuance more tightly.
56.13%
Slight usage while AVXL is negative at -56.14%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.43%
AP growth of 59.43% while AVXL is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-0.47%
Both reduce yoy usage, with AVXL at -56.14%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
85.22%
Some yoy increase while AVXL is negative at -99.43%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-64.88%
Both yoy CFO lines are negative, with AVXL at -176.24%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
82.30%
CapEx growth of 82.30% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.30%
We expand invests by 82.30% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
-39.13%
We cut debt repayment yoy while AVXL is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-90.34%
Both yoy lines negative, with AVXL at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.